Neurocrine biosciences presented one-year data from phase 3 cahtalyst™ studies showing improvements in weight-related effects of glucocorticoid treatment at the 2025 endocrine society's annual meeting

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with crenessity® (crinecerfont) achieved clinically meaningful weight reductions substantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with crenessity compared with placebo through one year of treatment san diego , july 14, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of new data from the phase 3 cahtalyst™ adult and pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with crenessity® (crinecerfont) for up to one year. these data were presented at the endocrine society's annual meeting, endo 2025, that is taking place july 12-15 in san francisco.
NBIX Ratings Summary
NBIX Quant Ranking